Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

HI-PRIX Health Innovation Next Generation Payment & Pricing Models

Coordinator
Universita Commerciale Luigi Bocconi, Italy
Runs
1 January 2023 to 31 December 2025
Status
Running
EU funding
€4.0m
Total cost
€4.0m
Partners
18 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101095593

What the project is doing

In the project's own words, from its summary on CORDIS.

The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use.

Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access.

Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.

Topics

Who is involved

OrganisationCityCountryRole
Universita Commerciale Luigi BocconiMilanoItalyCoordinator
Hta Austria - Austrian Institute for Health Technology Assessment GmbHWienAustriaParticipant
Universite Libre De BruxellesBruxellesBelgiumParticipant
University of HamburgHamburgGermanyParticipant
Escuela Andaluza De Salud Publica SAGranadaSpainParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Fundacion Publica Andaluza Progreso Y Salud M.p.SevillaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Servei Catala De La SalutBarcelonaSpainAssociatedpartner
Ecole D'economie De ParisParisFranceParticipant
Agenzia Italiana Del FarmacoRomaItalyAssociatedpartner
Vilniaus UniversitetasVilniusLithuaniaParticipant
Erasmus Universiteit RotterdamRotterdamNetherlandsParticipant
Infarmed - Autoridade Nacional Do Medicamento E Produtos Da Saude IpLisboaPortugalAssociatedpartner
Universidade Nova De LisboaLisboaPortugalParticipant
Imperial College of Science Technology and MedicineLondonUnited KingdomAssociatedpartner
London School of Economics and Political ScienceLondonUnited KingdomAssociatedpartner
The Office of Health EconomicsLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI